Abstract W P150: Incident Cancer in Stroke Survivors: Analysis of the Vitamin Intervention for Stroke Prevention (VISP) Trial
Background: Subclinical cancer can manifest as a thrombo-embolic event and may be detected at a later interval in stroke survivors.
Objective: To determine the rate of incident cancer in a large cohort of stroke survivors.
Methods: An analysis of the VISP trial was performed which was a randomized, double-blind trial conducted in 3680 adults with nondisabling cerebral infarction. The primary intervention was best medical/surgical management plus a daily vitamin B6, vitamin B12, and folic acid supplementation. The incidence of new cancer was identified using Kaplan Meir analysis over a mean (±SD) period of 24 (±1.4) months. Unadjusted survival probabilities were estimated by the Kaplan-Meier method for patients with and without incident cancer.
Results: A total of 3247 patients (mean age (±SD) of 66 (±11); 2013 were men) were cancer free at the time of enrollment. The incidence of new cancer was 0.15, 0.80, 1.2, and 2.0 per 100 patients at 1 month, 6 month, 1 year, and 2 years, respectively. Patients with incident cancer had lower body mass index (27.8±5.0 vs. 28.4±5.8, p=0.02), high density cholesterol (42.4±12.5 vs. 45.4±15.2, p=0.007) and triglyceride levels (160.1±88.4 vs. 175.6±162.3, p<0.0001) at baseline evaluation. The unadjusted 2 year survival was significantly lower in patients with incident cancer than those without incident cancer (85% versus 95.3%, p=<.0001). The rate of combined endpoint of recurrent stroke, myocardial infarction, and death was higher among those with incident cancer (24.6% versus 16%, p=0.01).
Conclusions: Incident cancer is not uncommon and is associated with lower survival among stroke survivors.
Author Disclosures: A.I. Qureshi: None. M.M. Adil: None. G.J. Rodriguez: None. S.A. Chaudhry: None. M.K. Suri: None.
- © 2014 by American Heart Association, Inc.